宜明昂科:于无声处听惊雷

Jo的随笔
02 Jun

Key Takes:· IMM2510 PD-L1/VEGF 亮相 ASCO大会· 国产6款 PD-1/VEGF Vs. PD-L1/VEGF 分析· 差异化优势的 CD47 资产· 不容忽视的 ActRIIA 资产在 2025 年 ASCO 年会上,康方生物与 Summit 合作的 PD-1/VEGF 依沃西单抗全球 III 期 HARMONi 研究公布顶线结果,该药联合化疗在无进展生存期(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10